Clinical Trials Logo

Lupus Nephritis clinical trials

View clinical trials related to Lupus Nephritis.

Filter by:

NCT ID: NCT01646736 Recruiting - Nephritis, Lupus Clinical Trials

Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis

Start date: July 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Evaluation the clinical efficacy and safety profile of glucocorticosteroid combined with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of patients with lupus nephritis. Open-labeled, randomized, prospective multi-center clinical trial. Observation period of 24 weeks.

NCT ID: NCT01539902 Recruiting - Lupus Nephritis Clinical Trials

Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis

hUC-MSC-SLE
Start date: February 2012
Phase: Phase 2
Study type: Interventional

The efficacy measure of hUC-MSC in the treatment of proliferative lupus nephritis on remission of lupus nephritis (combined partial and complete remission) in terms of stabilization and improvement in renal function.

NCT ID: NCT01226147 Recruiting - Lupus Nephritis Clinical Trials

Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis

Start date: September 2010
Phase: Phase 2
Study type: Interventional

An open-label study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Lupus Nephritis

NCT ID: NCT01172002 Recruiting - Lupus Clinical Trials

Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis

Start date: March 2010
Phase: N/A
Study type: Interventional

Leflunomide versus Azathioprine for Maintenance Therapy of Lupus Nephritis

NCT ID: NCT00441220 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Cyclophosphamide in Lupus Nephritis

Start date: October 2006
Phase: N/A
Study type: Observational

Cyclophosphamide is widely used in the treatment of cancer and autoimmune diseases such as lupus nephritis. However, there is considerable variability in the response to cyclophosphamide treatment. Cyclophosphamide is a pro-drug that requires initial activation by CYP liver enzymes. Recent clinical studies have indicated a possible role of one CYP enzyme, CYP2C19 in this activation step. This enzyme has a genetic polymorphism (variants which lack functional activity) and people who have inherited these variants are poor metabolisers of certain drugs. The aim of this study is to determine whether response to therapy in a New Zealand population of lupus nephritis patients is determined by cyclophosphamide bioactivation (the metabolic phenotype) and CYP genotype. Currently there is no way of predicting a patient's response to cyclophosphamide. An understanding of the factors which contribute to the therapeutic failure in lupus nephritis is particularly important due to the high morbidity and mortality associated with this disease. There are other treatment options for lupus nephritis patients who fail to respond to cyclophosphamide. If successful, this study may help identify patients who are unlikely to respond to cyclophosphamide and thus should not be unnecessarily be exposed to the drug and may justify the use of newer, more costly immunosuppressive drugs such as mycophenolate mofetil and rituximab.